Name:
Sir Patrick Vallance HonFBPhS
Organisation:
Year elected:
2014
Primary professional setting:
Government
Patrick Vallance is a clinician and clinical pharmacologist who has worked in academia and industry. He is President of GSK R&D and prior to joining industry was head of the Division of Medicine at UCL. His personal research was in the field of vascular pharmacology. Patrick has championed open innovation and recently founded Open Targets, to find important targets for new medicines based on genetic information. In 2016 GSK was the first company in the world to get a genetically modified cell treatment approved.He was elected to the fellowship of the Academy of Medical Sciences in 1999 and elected FRS in 2017. He has received numerous prizes and awards and delivered the President’s lecture for the BPS in 2014.